Table 1.
Characteristics of included studies.
| Study (y) | Tumor stage | Patients, exp/cont groups | Age (mean ± SD or median) (treatment/con) | Sex (male/female) | Exp regimens | Immunotherapy method | |
| Chang et al 2013 | III–IV | 33/33 | 66 (median) | 66 (median) | 43/23 | CT, CIK | 1 × 109 CIK cells |
| Hu et al 2012 | III–IV | 37/25 | ND | ND | 34/28 | CM, CT, CIK | >1 × 109 CIK cell |
| Liu et al 2011 | III–IV | 20/20 | 62 (median) | 62 (median) | 23/17 | CT, CIK | 0.6–1.6 × 1010 CIK cells |
| Qu et al 2015 | IV | 100/100 | 56.3 ± 7.5 (mean) | 56.3 ± 7.5 (mean) | ND | CT, CIK | ND |
| Shu et al 2015 | II–III | 30/30 | 57 (median) | 59 (median) | 39/21 | RT, CT, CIK | 5 × 1010 CIK cells |
| Wang et al 2014 | I–IV | 62/62 | ND | ND | 92/32 | CT, DC-CIK | 2 × 1010 DC-CIK cells |
| Wen et al 2015 | I–II | 41/35 | 59 (median) | 59 (median) | 43/33 | RT, CT, DC-CIK | ND |
| Xi et al 2015 | II–IIIB | 26/26 | 60 (median) | 62 (median) | 30/22 | Surgery, CT, DC-CIK | 3–4 × 109 DC-CIK cells |
| Xu et al 2018 | IV | 28/28 | 58 (median) | 56 (median) | 36/20 | CT, DC-CIK | ND |
| Xu et al 2010 | III–IV | 21/25 | 45 (median) | 42 (median) | 27/19 | CT, CIK | >5 × 109 CIK cells |
| Yan et al 2015 | I–IV | 34/34 | 70.5 ± 2.9 (mean) | 71.6 ± 2.2 (mean) | 45/23 | RT, DC-CIK | 5 × 109 CIK cells 5 × 107 DC cells |
| Yang et al 2016 | ND | 35/35 | 64.9 ± 1 (mean) | 65.3 ± 1.3 (mean) | 35/35 | CT, DC-CIK | 1.5 × 1010 DC-CIK cells |
| Yang et al 2015 | ND | 100/100 | 70.2 ± 7.3 (mean) | 72.3 ± 6.9 (mean) | 147/53 | CT, DC-CIK | ND |
| Zhang et al 2017 | II–IIIB | 30/30 | 64 ± 5.7 (mean) | 64.2 ± 5.9 (mean) | 35/25 | Surgery, CT, DC-CIK | 3–4 × 109 DC-CIK cells |
| Zhang et al 2016 | IV | 32/28 | 56.9 ± 8.9 (mean) | 56 ± 10.4 (mean) | 37/23 | CT, DC-CIK | >6 × 109 DC-CIK cells |
| Zhao et al 2015 | IIIB–IV | 50/50 | 55.9 ± 6.3 (mean) | 56.5 ± 5.5 (mean) | 62/38 | CT, DC-CIK | ND |
| Zhu et al 2014 | ND | 38/38 | 59.6 ± 1.3 (mean) | 59.8 ± 1.4 (mean) | 43/33 | CT, CIK | ND |
The table summarizes patients’ basic information regarding the tumor stage, treatment, regimens, cases, age and cell doses of the immunotherapy.
CIK = cytokine-induced killer cell, CM = Chinese medicine (Huisheng oral liquid), Cont = control group, CT = chemotherapy, DC = dendritic cell, Exp = experimental group, ND = not determined, RT = radiotherapy.